1
|
Echeverria GV, Ge Z, Seth S, Jeter-Jones SL, Zhang X, Zhou X, Cai S, Tu Y, McCoy A, Peoples M, Lau R, Shao J, Sun Y, Bristow C, Carugo A, Ma X, Harris A, Wu Y, Moulder S, Symmans WF, Marszalek JR, Heffernan TP, Chang JT, Piwnica-Worms H. Abstract GS5-05: Resistance to neoadjuvant chemotherapy in triple negative breast cancer mediated by a reversible drug-tolerant state. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-gs5-05] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Approximately 50% of patients with localized triple negative breast cancer (TNBC) have substantial residual cancer burden following treatment with neoadjuvant chemotherapy (NACT), resulting in distant metastasis and death for most of these patients. While genomic and phenotypic intra-tumor heterogeneity are pervasive features of TNBCs at the time of diagnosis, the functional contributions of heterogeneous tumor cell populations to chemoresistance have not been elucidated.
To investigate tumor evolution accompanying NACT, we employed orthotopic patient-derived xenograft (PDX) models of treatment-naïve TNBC, which retain intra-tumor heterogeneity characteristic of human TNBC. We discovered that some PDX models initially exhibited partial sensitivity to standard front-line NACT (Adriamycin plus Cytoxan, AC). Following AC, residual tumors were resistant to chemotherapy but repopulated tumors with chemo-sensitive cells if left untreated, indicating that tumor cells possessed inherent plasticity. To identify the tumor cell subpopulation(s) conferring chemoresistance, we conducted barcode-mediated clonal tracking in three independent PDX models by introducing a high-complexity pooled lentiviral barcode library into PDX tumor cells which were then orthotopically engrafted into recipient mice. Strikingly, residual tumors maintained the same heterogeneous clonal architecture as naïve tumors. Concordantly, whole-exome sequencing revealed conservation of genomic subclonal architecture throughout treatment. These results were corroborated by genomic sequencing of serial biopsies pre- and post-AC obtained directly from TNBC patients enrolled on an ongoing clinical trial at MD Anderson (ARTEMIS; NCT02276443). Together, these studies revealed that genomically distinct pre-treatment subclones were equally capable of surviving AC to reconstitute tumors after treatment.
To identify functional addictions of residual tumor cells, we conducted histologic and transcriptomic profiling. Residual tumors following AC-treatment exhibited extensive fibrotic desmoplasia and tumor cell pleomorphism in both PDX models and in serial biopsies obtained from TNBC patients enrolled on the ARTEMIS trial. Strikingly, these AC-induced features were reverted upon regrowth of residual tumors in PDXs and in patients' tumors. Similarly, residual tumors exhibited unique transcriptomic features, many of which are also de-regulated in cohorts of human TNBCs undergoing chemotherapy treatment. These features were nearly completely reverted after tumors regrew, suggesting that the residual tumor state may be a unique and transient therapeutic window. Gene set enrichment analyses revealed that residual tumors had increased activation of oxidative phosphorylation and decreased glycolytic signaling. Pharmacologic targeting of oxidative phosphorylation with a small-molecule inhibitor of mitochondrial electron transport chain complex I (IACS-010759) significantly delayed the regrowth of AC-treated residual tumors in three independent PDX models. Collectively, these studies reveal that a reversible phenotypic state can confer chemoresistance in the absence of genomic selection and that the residual tumor state is a novel therapeutic window for chemo-refractory TNBC.
Citation Format: Echeverria GV, Ge Z, Seth S, Jeter-Jones SL, Zhang X, Zhou X, Cai S, Tu Y, McCoy A, Peoples M, Lau R, Shao J, Sun Y, Bristow C, Carugo A, Ma X, Harris A, Wu Y, Moulder S, Symmans WF, Marszalek JR, Heffernan TP, Chang JT, Piwnica-Worms H. Resistance to neoadjuvant chemotherapy in triple negative breast cancer mediated by a reversible drug-tolerant state [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr GS5-05.
Collapse
Affiliation(s)
- GV Echeverria
- The University of Texas MD Anderson Cancer Center, Houston, TX; The University of Texas Health Science Center, Houston, TX
| | - Z Ge
- The University of Texas MD Anderson Cancer Center, Houston, TX; The University of Texas Health Science Center, Houston, TX
| | - S Seth
- The University of Texas MD Anderson Cancer Center, Houston, TX; The University of Texas Health Science Center, Houston, TX
| | - SL Jeter-Jones
- The University of Texas MD Anderson Cancer Center, Houston, TX; The University of Texas Health Science Center, Houston, TX
| | - X Zhang
- The University of Texas MD Anderson Cancer Center, Houston, TX; The University of Texas Health Science Center, Houston, TX
| | - X Zhou
- The University of Texas MD Anderson Cancer Center, Houston, TX; The University of Texas Health Science Center, Houston, TX
| | - S Cai
- The University of Texas MD Anderson Cancer Center, Houston, TX; The University of Texas Health Science Center, Houston, TX
| | - Y Tu
- The University of Texas MD Anderson Cancer Center, Houston, TX; The University of Texas Health Science Center, Houston, TX
| | - A McCoy
- The University of Texas MD Anderson Cancer Center, Houston, TX; The University of Texas Health Science Center, Houston, TX
| | - M Peoples
- The University of Texas MD Anderson Cancer Center, Houston, TX; The University of Texas Health Science Center, Houston, TX
| | - R Lau
- The University of Texas MD Anderson Cancer Center, Houston, TX; The University of Texas Health Science Center, Houston, TX
| | - J Shao
- The University of Texas MD Anderson Cancer Center, Houston, TX; The University of Texas Health Science Center, Houston, TX
| | - Y Sun
- The University of Texas MD Anderson Cancer Center, Houston, TX; The University of Texas Health Science Center, Houston, TX
| | - C Bristow
- The University of Texas MD Anderson Cancer Center, Houston, TX; The University of Texas Health Science Center, Houston, TX
| | - A Carugo
- The University of Texas MD Anderson Cancer Center, Houston, TX; The University of Texas Health Science Center, Houston, TX
| | - X Ma
- The University of Texas MD Anderson Cancer Center, Houston, TX; The University of Texas Health Science Center, Houston, TX
| | - A Harris
- The University of Texas MD Anderson Cancer Center, Houston, TX; The University of Texas Health Science Center, Houston, TX
| | - Y Wu
- The University of Texas MD Anderson Cancer Center, Houston, TX; The University of Texas Health Science Center, Houston, TX
| | - S Moulder
- The University of Texas MD Anderson Cancer Center, Houston, TX; The University of Texas Health Science Center, Houston, TX
| | - WF Symmans
- The University of Texas MD Anderson Cancer Center, Houston, TX; The University of Texas Health Science Center, Houston, TX
| | - JR Marszalek
- The University of Texas MD Anderson Cancer Center, Houston, TX; The University of Texas Health Science Center, Houston, TX
| | - TP Heffernan
- The University of Texas MD Anderson Cancer Center, Houston, TX; The University of Texas Health Science Center, Houston, TX
| | - JT Chang
- The University of Texas MD Anderson Cancer Center, Houston, TX; The University of Texas Health Science Center, Houston, TX
| | - H Piwnica-Worms
- The University of Texas MD Anderson Cancer Center, Houston, TX; The University of Texas Health Science Center, Houston, TX
| |
Collapse
|
2
|
Shariati M, Paez-Arango N, Bristow CA, Evans KW, Peoples MD, Carugo A, Heffernan TP, Meric-Bernstam F. Abstract P6-18-13: Identification of optimal combination therapy partners for PI3K/Akt/mTOR pathway inhibitor in triple negative breast cancer. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p6-18-13] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Triple-negative breast cancer (TNBC) is among the most aggressive subtypes, accounts for 10-15% of all breast cancer cases and is characterized by a lack of hormone receptors with a low overall survival rate. Due to the heterogeneity nature of this disease, the absence of validated molecular targets makes it unresponsive to conventional therapies. PI3K/Akt/mTOR pathway is aberrantly activated in TNBC, but single agent therapy is commonly subject to resistance. The goal of this study is to identify the genes that can be targeted to enhance the efficacy of mTOR inhibitor TAK228, an agent that is being investigated as a treatment for advanced solid tumors, in TNBC with PI3K pathway activation. We utilized an in vivo pooled barcoded shRNA library screening to determine the genes that have the potential to be used as TAK228 synthetic lethal partners. Using deep sequencing analysis of the shRNA profiles, we identified several genes whose loss of function conferred synthetic lethality in the presence of TAK228. We found that targeting the candidate genes (WEE1, BMX and MAPK15) with their inhibitors (AZD1775, Ibrutinib and Sunitinib) did not significantly affect the viability, however combination treatment of these agents with TAK228 induced a robust growth inhibition and demonstrated a significant synergy in MDA-MB-468 cell lines. Investigating the activation of relevant survival signaling pathways will further elucidate the mechanism of synthetic lethal interaction. These observations provide a promising rational strategy for the treatment of TNBC with PI3K pathway aberration.
Citation Format: Shariati M, Paez-Arango N, Bristow CA, Evans KW, Peoples MD, Carugo A, Heffernan TP, Meric-Bernstam F. Identification of optimal combination therapy partners for PI3K/Akt/mTOR pathway inhibitor in triple negative breast cancer [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P6-18-13.
Collapse
Affiliation(s)
- M Shariati
- The Uniaversity of Texas MD Anderson Cancer Center, Houston, TX
| | - N Paez-Arango
- The Uniaversity of Texas MD Anderson Cancer Center, Houston, TX
| | - CA Bristow
- The Uniaversity of Texas MD Anderson Cancer Center, Houston, TX
| | - KW Evans
- The Uniaversity of Texas MD Anderson Cancer Center, Houston, TX
| | - MD Peoples
- The Uniaversity of Texas MD Anderson Cancer Center, Houston, TX
| | - A Carugo
- The Uniaversity of Texas MD Anderson Cancer Center, Houston, TX
| | - TP Heffernan
- The Uniaversity of Texas MD Anderson Cancer Center, Houston, TX
| | | |
Collapse
|